A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1

Trial Profile

A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Baliforsen (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 16 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top